위장관 ; 한국인의 위,십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율 = Primary Antibiotic Resistance of Helicobacter pylori Strains and Eradication Rate according to Gastroduodenal Disease in Korea한국인의 위,십이지장 질환에 따른 Helicobacter pylori 균주의 일차 항생제 내성과 H. pylori 제균율

다국어 초록 (Multilingual Abstract)

Background/Aims: This study was performed to evaluate whether the prevalence rates of primary antibiotic resistance in Helicobacter pylori (H. pylori) isolates and the eradication rate of H. pylori could be different between cancer and non-cancer patients. Methods: H. pylori were isolated from gastric mucosal biopsy specimens obtained from 269 Koreans, who did not have any eradication therapy history and were diagnosed as one of the following diseases; chronic gastritis, benign gastric ulcer, duodenal ulcer or gastric cancer. The susceptibilities of the H. pylori isolates to amoxicillin, clarithromycin, metronidazole, tetracycline, azithromycin, ciprofloxacin, levofloxacin and moxifloxacin were examined with the agar dilution method. In addition, eradication rate of H. pylori was evaluated. Results: There was no significant difference in the primary antibiotic resistance to above eight antibiotics among chronic gastritis, peptic ulcer disease and gastric cancer. Furthermore there was no difference of antibiotic resistance between cancer and non-cancer patients, and there was no difference of eradication rate of H. pylori according to disease. Conclusions: Primary antibiotic resistance and H. pylori eradication rate were not different between cancer and non-cancer patients. (Korean J Gastroenterol 2011;58:74-81)

참고문헌 (Reference)

1 김나영, "헬리코박터 파일로리 감염의 진단 및 치료 가이드라인" 대한소화기학회 54 (54): 269-278, 2009

2 김재연, "한국에서 지역에 따른 Helicobacter pylori 균주 내성" 대한소화기학회 57 (57): 221-229, 2011

3 Korean H, "pylori Study Group. Diagnosis and treatment of Helicobacter pylori infection in Korea" 32 : 275-289, 1998

4 Kim MN, "The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication" 13 : 261-268, 2008

5 Lind T, "The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies" 116 : 248-253, 1999

6 Gisbert JP, "Systematic review and meta-analysis: levofloxacin- based rescue regimens after Helicobacter pylori treatment failure" 23 : 35-44, 2006

7 Kostamo P, "Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland" 37 : 22-25, 2011

8 Graham DY, "New concepts of resistance in the treatment of Helicobacter pylori infections" 5 : 321-331, 2008

9 "NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease" 272 : 65-69, 1994

10 Yoon H, "Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate" 14 : 77-85, 2009

11 Kim JJ, "Mixed-infection of antibiotic susceptible and resistant Helicobacter pylori isolates in a single patient and underestimation of antimicrobial susceptibility testing" 8 : 202-206, 2003

12 Kim N, "Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea" 40 : 683-687, 2006

13 Kwon DH, "High-level beta-lactam resistance associated with acquired multidrug resistance in Helicobacter pylori" 47 : 2169-2178, 2003

14 Uemura N, "Helicobacter pylori infection and the development of gastric cancer" 345 : 784-789, 2001

15 Kim YS, "Helicobacter pylori genotyping findings from multiple cultured isolates and mucosal biopsy specimens: strain diversities of Helicobacter pylori isolates in individual hosts" 21 : 522-528, 2009

16 Gisbert JP, "Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia" 13 : 1303-1307, 2001

17 Matsukura N, "Helicobacter pylori eradication therapy for the remnant stomach after gastrectomy" 6 : 100-107, 2003

18 Mégraud F, "H. pylori antibiotic resistance: prevalence, importance, and advances in testing" 53 : 1374-1384, 2004

19 Chung SJ, "Eradication rates of Helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease" 54 : 1293-1296, 2007

20 Jang S, "Epidemiological link between gastric disease and polymorphisms in VacA and CagA" 48 : 559-567, 2010

21 Uemura N, "Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer" 6 : 639-642, 1997

22 Kim JM, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea" American Society for Microbiology 48 (48): 4843-4847, 2004

23 Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report" 16 : 167-180, 2002

24 Kobayashi I, "Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005" 45 : 4006-4010, 2007

25 Hwang TJ, "Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea" 44 : 536-543, 2010

26 Ivashkin VT, "Azithromycin in a triple therapy for H. pylori eradication in active duodenal ulcer" 8 : 879-882, 2002

27 Gerrits MM, "Alterations in penicillin-binding protein 1A confer resistance to beta-lactam antibiotics in Helicobacter pylori" 46 : 2229-2233, 2002

28 Li Y, "Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis" 122 : 413-422, 2010

29 Rhead JL, "A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer" 133 : 926-936, 2007